The P2Y 13 receptor has recently been identified as a new P2Y receptor sharing a high sequence homology with the P2Y 12 receptor as well as similar functional properties: coupling to G i and responsiveness to ADP (Communi et al., 2001) . In the present study, the pharmacology of the P2Y 13 receptor and its differences with that of the P2Y 12 Similarly, 2MeSADP was more potent than ADP in stimulating IP 3 accumulation after 10 min in AG32 cells and increasing cAMP in pertussis toxin-treated CHO-K1 cells stimulated by forskolin. On the other hand, ADP and 2MeSADP were equipotent at stimulating IP 3 formation in AG32 cells after 30 s and inhibiting forskolininduced cAMP accumulation in CHO-K1 cells. These differences in potency cannot be explained by differences in degradation rate, which in AG32 cells was similar for the two nucleotides. When contaminating diphosphates were enzymatically removed and assay of IP 3 was performed after 30 s, ATP and 2MeSATP seemed to be weak partial agonists of the P2Y 13 receptor expressed in AG32 cells. The stimulatory effect of ADP on the P2Y 13 receptor in AG32 cells was antagonized by reactive blue 2, suramin, pyridoxal-phosphate-6-azophenyl-2Ј,4Јdisulfonic acid, diadenosine tetraphosphate, and 2-(propylthio)-5Ј-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (AR-C67085MX), but not by N 6
S] binding to membranes prepared from the same cells. Similarly, 2MeSADP was more potent than ADP in stimulating IP 3 accumulation after 10 min in AG32 cells and increasing cAMP in pertussis toxin-treated CHO-K1 cells stimulated by forskolin. On the other hand, ADP and 2MeSADP were equipotent at stimulating IP 3 formation in AG32 cells after 30 s and inhibiting forskolininduced cAMP accumulation in CHO-K1 cells. These differences in potency cannot be explained by differences in degradation rate, which in AG32 cells was similar for the two nucleotides. When contaminating diphosphates were enzymatically removed and assay of IP 3 was performed after 30 s, ATP and 2MeSATP seemed to be weak partial agonists of the P2Y 13 receptor expressed in AG32 cells. The stimulatory effect of ADP on the P2Y 13 receptor in AG32 cells was antagonized by reactive blue 2, suramin, pyridoxal-phosphate-6-azophenyl-2Ј,4Јdisulfonic acid, diadenosine tetraphosphate, and 2-(propylthio)-5Ј-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (AR-C67085MX), but not by N 6 -methyl 2Ј-deoxyadenosine 3Ј,5Ј-bisphosphate (MRS-2179) (up to 100 M). The most potent antagonist was N 6 -(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5Ј-adenylic acid, monoanhydride with dichloromethylenebis (phosphonic acid) (AR-C69931MX) (IC 50 ϭ 4 nM), which behaved in a noncompetitive way. The active metabolite of clopidogrel was unable to displace bound 2MeSADP at concentrations up to 2 M.
P2Y receptors are G protein-coupled receptors that are activated by extracellular nucleotides (Ralevic and Burnstock, 1998) . A large variety of physiological functions is mediated by extracellular purine and pyrimidine nucleotides via P2Y receptors. For example, ADP activates platelet P2Y 1 and P2Y 12 receptors that play a crucial role in thrombus formation and stabilization (Fabre et al., 1999; Leon et al., 1999; Foster et al., 2001; Turner et al., 2001) . ATP and UTP stimulate the airway mucociliary escalator via P2Y 2 , and possibly P2Y 4 and P2Y 6 , receptors that are expressed on epithelial cells (Communi et al., 1999) and represent potential targets for the therapy of cystic fibrosis and other pulmonary obstructive diseases (Cressman et al., 1999) . ATP seems to play a role in the immune system through the P2Y 11 receptor activation that leads to granulocytic differentiation (Communi et al., 2000) and dendritic cell maturation (Wilkin et al., 2001) .
The recent molecular cloning of the platelet ADP receptor P2Y 12 (Hollopeter et al., 2001 ) revealed the existence of two structurally-distinct subfamilies of P2Y receptors. The first one is composed of P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , and P2Y 11 receptors, all coupled to the phospholipase C pathway, except P2Y 11 , which is also positively coupled to the cAMP pathway. The members of the second subfamily are P2Y 12 , P2Y 13 , and the UDP-glucose receptor recently renamed P2Y 14 , which are all coupled to G i . This group shows a low amino acid identity with the other P2Y receptors but shares some conserved positively charged amino acids in TM6 and TM7 (Erb et al., 1995) . The P2Y 12 receptor is the target of antithrombotic agents: clopidogrel, which acts via the covalent binding of an active metabolite (Savi et al., 2001) , and ATP derivatives (AR-C69931MX, etc.), which behave as competitive antagonists (Ingall et al., 1999) .
The human P2Y 13 receptor was recently identified (Communi et al., 2001; Zhang et al., 2002) . Its sequence displays 48% amino acid identity with the P2Y 12 receptor. It is coupled to G i and responds to diphosphate adenine nucleotides (ADP, 2MeSADP, ADP␤S). The abundance of P2Y 13 messengers is highest in the brain and the spleen, suggesting roles in nervous and immune systems. As a preliminary step to the evaluation of its potential physiological roles, we have now performed a detailed pharmacological characterization of the P2Y 13 receptor.
Materials and Methods
Cell Culture and Transfection. CHO-K1 and AG32 cells were transfected with the recombinant P2Y 13 -pEFIN5 plasmid or the plasmid alone using FuGENE6 transfection reagent (Roche Applied Science, Mannheim, Germany) as described previously (Communi et al., 2001 (Brea, CA) . The active metabolite of clopidogrel was obtained as described previously (Savi et al., 2000) .
Binding (Savi et al., 1994) . When the cultures were 80% confluent, the cells were harvested in phosphatebuffered saline-EDTA (5 mM), washed once, and resuspended in dialyzed fetal calf serum containing culture medium, supplemented with 1 mM EDTA, and used within 15 min. Incubations were carried out in 0.20 ml of culture medium that contained P2Y 13 -expressing 1321N1 cells (5000 cells/well) and [
33 P]2MeSADP (0 to 3 nM). Triplicate incubations were carried out at 20°C for 10 min and were stopped by the addition of 3 ml of ice-cold assay buffer followed by a rapid vacuum filtration over glass fiber filter (Filtermats 11734; Skatron Instruments Inc., Sterling, VA D-glucose) . The cells were then incubated in presence of the tested compounds for 30 s up to 10 min. The incubation was stopped by the addition of 1 ml of an ice-cold 3% perchloric acid solution. Inositol phosphates were extracted and separated on Dowex columns as described previously (Communi et al., 1995) .
Cyclic AMP Assays. CHO-K1 Chinese hamster ovary cells were seeded (150,000 cells per dish) on 35-mm (diameter) Petri dishes in Ham's F-12 medium containing 10% fetal calf serum, antibiotics, amphotericin, sodium pyruvate, and 400 g/ml G418. Cells were incubated for 2 h in KRH (see below) containing rolipram (25 M) and incubated in the presence of the tested compound for 10 min with or without forskolin (3 M). The incubation was stopped by the addition of 1 ml of HCl (0.1 M). The cellular lysate was dried and resuspended in an appropriate volume of water. Cyclic AMP was quantified by 125 I radioimmunoassay as described previously (Brooker et al., 1979) .
Evaluation of Nucleotide Degradation. AG32 cells were seeded (200,000 cells per dish) on 35-mm (diameter) Petri dishes in inositol-free Dulbecco's modified Eagle's medium containing 5% fetal calf serum, antibiotics, amphotericin, sodium pyruvate, and 400 g/ml G418. Cells were incubated for 2 h in KRH buffer. Cells were then incubated in the presence of 100 nM [ 3 H]ADP or 100 nM [ 3 H]2MeSADP for various times. Cell supernatants were filtered through a 0.4-m filter (Millipore, Brussels, Belgium) and stored at Ϫ20°C. Radiolabeled nucleotides were separated by HPLC on a Bondapack C18 reverse phase 3.9 ϫ 300 mm column (Millipore) and eluted at 1.5 ml/min with a linear methanol gradient between solution A (5 mM TBAP, 60 mM KH 2 PO 4 , and 5% methanol) and solution B (5 mM TBAP, 60 mM KH 2 PO 4 , and 35% methanol) at 2% per min. HPLC fractions were counted after addition of scintillation liquid, Insta-Gel II Plus (PerkinElmer). The column was calibrated using unlabeled nucleotides (AMP, ADP, ATP, 2MeSAMP, 2Me- Nucleotide Pretreatment. To eliminate contaminating diphosphate nucleotides, triphosphate nucleotides were pretreated as described previously (Hechler et al., 1998) . In brief, ATP and 2MeSATP (1 mM solutions) were incubated for 90 min at room temperature with 20 units/ml CPK and 10 mM CP. The reaction was stopped by addition of 10 mM iodoacetamide. Apyrase (grade I) was also used as another way to remove the contaminating diphosphate nucleotides. In brief, poly[A] and ADP (10 mM solutions) were incubated for 5 min at 30°C in HEPES buffer, pH ϭ 6.5, with 20 units/ml apyrase (grade I). The apyrase activity was checked by HPLC using the same conditions as described in the previous section.
Data Analysis. Graphs and data analysis were performed with Prism from GraphPad Software (San Diego, CA). (Fig. 1A) . The Scatchard plot (Fig. 1B) revealed the presence of one class of binding sites that exhibit high affinity with an apparent equilibrium dissociation constant (K d ) of 0.28 Ϯ 0.12 nM. The total number of binding sites (B max ) corresponds to 72,240 Ϯ 18,540 receptors per cell.
Results

Assay
As shown in Fig. 1C and Table 1 , the order of affinity for the receptor was 2MeSADP Ͼ Ͼ 2MeSATP Ͼ ADP ϭ AR-C67085MX Ͼ ADP␤S ϭ ATP␥S ϭ ATP. The active metabolite of clopidogrel (Savi et al., 2000) , a potent antagonist of the P2Y 12 receptor (Savi et al., 2001) 35 S] was assessed on membranes of both 1321N1 and AG32 cells transfected with P2Y 13 -pEFIN5 vector. The same results were found with both cell lines. As shown in Fig. 2A , the binding of GTP␥[
35 S] increased progressively after the addition of ADP or 2MeSADP. At all the times tested, the effect of 2MeSADP was greater than that of ADP. As shown in Fig.  2B , after 15 min of incubation, 2MeSADP was at least 30 times more potent than ADP. The binding of GTP␥[
35 S] induced by 30 nM of ADP or 2MeSADP was abolished by a 20-h preincubation with pertussis toxin (100 ng/ml) (data not shown) or by coincubation with AR-C67085MX (5 M) (Fig.  2C) . In 1321N1 cells not transfected with the P2Y 13 receptor, neither ADP nor 2MeSADP had an effect on GTP␥[
35 S] binding (data not shown).
Kinetics of IP 3 Formation in AG32 Cells. We studied the time course of IP 3 accumulation in AG32 cells stably expressing the P2Y 13 receptor using two distinct P2Y 13 agonists: ADP and 2MeSADP. As shown in Fig. 3A , the 2Me-SADP-induced IP 3 accumulation had a longer duration than the response to ADP. The peak of IP 3 accumulation was at 1 min and 30 s, respectively, for 2MeSADP and ADP. The concentration-action curves characterizing the effects of ADP, 2MeSADP, and ADP␤S on IP 3 formation after 30 s have been reported previously (Communi et al., 2001 ): they were almost superimposable for ADP and 2MeSADP; ADP␤S was slightly less potent. We have now obtained the corresponding concentration-action curves after 10 min, in experiments performed in the presence of LiCl (10 mM) and 8-p-SPT (100 M), to prevent an effect of adenosine formed by ADP degradation on the A 2 receptor endogenously expressed by 1321N1 cells. As shown in Fig. 3B , after 10 min of stimulation, the 2MeSADP concentration-action curve was shifted to the left compared with the 30-s stimulation, whereas the ADP and ADP␤S curves were shifted to the right. In these 10-min experiments, the following EC 50 values were computed for ADP, 2MeSADP, and ADP␤S, respectively: 194 Ϯ 26, 1.2 Ϯ 0.3, and 280 Ϯ 63 nM (mean Ϯ S.D. of three independent experiments). For 30-s experiments, the following EC 50 values were computed for ADP, 2MeSADP, and ADP␤S, respectively: 45 Ϯ 4.7, 57 Ϯ 19, and 82 Ϯ 13 nM (mean Ϯ S.D. of three independent experiments). The timedependent variation of the relative potencies of ADP and 2MeSADP cannot be explained by differences in the degradation rate, which was very similar for the two nucleotides (Fig. 4) .
ATP and 2MeSATP Effect on IP 3 in AG32 Cells. ATP and 2MeSATP were tested on the hP2Y 13 -expressing AG32 cells. Commercial powders are contaminated by degradation products: contamination by the respective diphosphate derivative is around 1% for ATP and 10% for 2MeSATP (Hechler et al., 1998) . Therefore, the diphosphate contaminants were enzymatically removed using CP/CPK as described under (Fig.  7B) .
Effect of Selective and Nonselective Antagonists on IP 3 in AG32 Cells. The classic nonselective antagonists of P2 receptors, RB-2, suramin, and PPADS (von Kugelgen and Wetter, 2000) , were tested on the hP2Y 13 receptor in the presence of 100 nM of ADP. As shown in Table 2 and Fig. 8A , all three agents were inhibitory: RB-2 was slightly more potent than suramin, whereas PPADS was significantly less potent. We also tested three selective P2Y antagonists cur- rently available: AR-C67085MX and AR-C69931MX, reported to be selective for P2Y 12 (Ingall et al., 1999) , and MRS-2179, selective for P2Y 1 . As shown in Fig. 8B , AR-C67085MX and AR-C69931MX were able to completely inhibit the response to 100 nM ADP with IC 50 values of 0.63 and 4.6 nM, respectively. The action of AR-C69931MX was noncompetitive (Fig. 8C) . At 100 M, MRS-2179 had almost no effect on IP 3 accumulation induced by 100 nM ADP (data not shown). As shown in Fig. 8D , MRS-2179 and PPADS were unable to displace [ 33 P]2MeSADP bound to 1321N1 cells expressing P2Y 13 , whereas suramin and RB-2 could partially displace [ 33 P]2MeSADP at high concentration. These results suggest that PPADS, suramin, and RB-2 act, at least in part, by a noncompetitive mechanism. Furthermore, RB-2, suramin, and PPADS (100 M) had no specificity for the P2Y 13 receptor, because they also inhibited the IP 3 response to adenosine that in AG32 cells results from the coupling to G␣ 16 of an endogenous adenosine receptor normally coupled to G s (Communi et al., 1999) (Fig.  8E ). As shown in Fig. 8F , two other nucleotides that are antagonists of P2Y 12 receptor were tested: Ap 4 A (Zamecnik et al., 1992) and 2MeSAMP (Hollopeter et al., 2001 ). Ap 4 A was a complete antagonist of hP2Y 13 with an IC 50 of 216 nM. In contrast, 2MeSAMP behaved as a partial agonist, producing a maximal effect that was 38% of that of ADP. Consistent with that partial agonist property, increasing amounts of 2MeSAMP decreased ADP-promoted IP 3 level by 62%, with an IC 50 of 2.4 M.
Effect on cAMP in CHO-K1 Cells. As shown in Fig. 9A , ADP and 2MeSADP produced a comparable inhibition of forskolin (3 M)-induced accumulation of cAMP in CHO-K1 cells stably expressing the P2Y 13 receptor. The IC 50 values of ADP and 2MeSADP were 0.07 Ϯ 0.14 and 0.1 Ϯ 0.3 nM, respectively (mean Ϯ S.D. of three independent experiments). The maximal inhibition was of 49 Ϯ 7.6% at 10 nM for ADP and of 54 Ϯ 9.7% at 1 nM for 2MeSADP (mean Ϯ S.D. of three independent experiments). At higher concentrations, the inhibition was reversed. The EC 50 values charac- terizing that reversal were strikingly different for 2MeSADP and ADP: 6.3 Ϯ 2 and 397 Ϯ 130 nM, respectively (mean Ϯ S.D. of three independent experiments). After an 18-h pretreatment with 100 ng/ml pertussis toxin, ADP and 2Me-SADP produced only enhancement of cAMP accumulation in response to forskolin (3 M) (Fig. 9B) . The EC 50 values of 2MeSADP and ADP were 4.2 Ϯ 1.6 and 158 Ϯ 15 nM, respectively (mean Ϯ S.D. of three independent experiments).
Discussion
The human P2Y 13 receptor was initially characterized after stable expression in 1321N1 cells coexpressing G␣ 16 (AG32 cells) and CHO-K1 cells (Communi et al., 2001) . In AG32 cells, but not in 1321N1 cells, ADP, 2MeSADP, and ADP␤S stimulated inositol phosphate formation in a pertussis toxin-sensitive manner. In CHO-K1 cells, ADP inhibited forskolin-induced cAMP accumulation, an effect that was abolished by pertussis toxin. Therefore, the P2Y 13 receptor was defined as a receptor for diphosphate adenine nucleotides coupled to G i (Communi et al., 2001) . Using different expression systems, Zhang et al. (2002) reached essentially similar conclusions. In the present study, we have further characterized the pharmacology of the P2Y 13 receptor and its differences with that of the P2Y 12 receptor, with the use of additional assays (binding of [ 33 P]2MeSADP and GTP␥[ 35 S]) and a special emphasis on the following issues: activity of triphosphate adenine nucleotides, relative potency of ADP and 2MeSADP, sensitivity to P2Y 12 antagonists (clopidogrel active metabolite, AR-C67085MX, and AR-C69931MX).
When contaminating diphosphates were enzymatically removed and testing was performed over a short period (30 s), ATP and 2MeSATP seemed to be partial agonists of the P2Y 13 receptor with a weak potency. In the radioligand binding assay, the IC 50 of 2MeSATP was 20-fold greater than that of 2MeSADP, but this difference is likely to have been underestimated because of ectonucleotidase-catalyzed conversion of 2MeSATP into 2MeSADP during the 10-min course of the assay. In contrast, 2MeSATP has been consistently reported by several groups to be almost equipotent to 2Me-SADP at the P2Y 12 receptor (Savi et al., 2001; Takasaki et al., 2001; Zhang et al., 2001) , although it is known that 2MeSATP behaves as an antagonist rather than an agonist of the P2Y 12 receptor natively expressed on platelets (Park and Hourani, 1999) . Zhang et al. (2002) have reported that after CP/CPK treatment, 2MeSATP retains a high potency on the P2Y 13 receptor (EC 50 ϭ 83 nM): the reason for this discrepancy with our data are unclear but might be related to different levels of receptor expression. Palmer et al. (1998) have indeed shown that the capacity of ATP to activate the P2Y 1 receptor depends on the degree of receptor reserve. Fig. 6 . Effect of different diadenosine polyphosphates on hP2Y 13 . 1321N1 cells transfected with both hP2Y 13 receptor and G␣ 16 protein were challenged for 30 s with two different concentrations (100 nM and 10 M) of ADP or ApnA (n ϭ 3 to 6). The data represent the mean Ϯ S.D. of triplicate experimental points obtained from one experiment that was representative of three. 2MeSADP is 1 to 2 orders of magnitude more potent than ADP at the human P2Y 12 receptor (Hollopeter et al., 2001; Savi et al., 2001; Takasaki et al., 2001; Zhang et al., 2001) . The situation seems more complex in the case of the P2Y 13 receptor. Binding of [ 33 P]2MeSADP to intact 1321N1 cells revealed a greater affinity of 2MeSADP compared with ADP. 2MeSADP was also more potent than ADP in stimulating the binding of GTP␥[
35 S] to 1321N1 or AG32 membranes, and this difference was observed at all the times tested. However, in AG32 cells, the EC 50 values characterizing the effects of 2MeSADP and ADP on IP 3 measured after 30 s have been reported to be almost equal (Communi et al., 2001) . Using a different expression system, Zhang et al. (2002) reported EC 50 values of 19 and 60 nM, respectively. We have now shown that the relative potencies of 2MeSADP and ADP are critically dependent on the experimental conditions. In AG32 cells, the ADP and 2MeSADP EC 50 values for IP 3 accumulation were almost equal after 30 s. However, a 200-fold difference was noticed after 10 min, because of decreased potency of ADP and increased potency of 2MeSADP. Degradation by ectonucleotidases cannot explain these discrepancies because the degradation rates of ADP and 2MeSADP were comparable and relatively slow. Neither can they be considered an artifact resulting from the use of G␣ 16 -mediated activation of phospholipase C as a readout of receptor activation. Indeed, using the GTP␥[
35 S] binding assay, 2MeSADP was more potent than ADP in both plain 1321N1 cells and 1321N1 cells cotransfected with G␣ 16 (AG32 cells). Furthermore, discrepancies were also found in CHO-K1 cells where G␣ 16 was not coexpressed. In CHO-K1 cells incubated for 10 min, ADP and 2MeSADP produced an equipotent inhibition of cAMP. However, the reversal of that inhibition at higher concentration, as well as the enhancement of cAMP accumulation observed after pertussis toxin pretreatment, were characterized by a greater potency of 2MeSADP. These effects are explained by a promiscuous coupling to G s , which has been observed with several other G i -coupled receptors (Kukkonen et al., 2001) . Although the binding assays indicate that 2MeSADP is intrinsically more potent than ADP at the P2Y 13 receptor, as it is on the P2Y 12 receptor, the other results, taken together, suggest that the P2Y 13 receptor could exist in multiple active conformations, characterized by differences in affinity for 2MeSADP versus ADP, kinetics, and preference for G proteins (Leff et al., 1997) .
The antiplatelet and antithrombotic action of clopidogrel is mediated by an active metabolite (Savi et al., 2000) . That active metabolite has been shown to prevent the binding of [ 33 P]2MeSADP to the P2Y 12 receptor with an IC 50 of 100 nM (Savi et al., 2001) . When the same radioligand binding assay was performed on the P2Y 13 receptor, no displacement of the ligand was observed at concentrations up to 2 M. On the other hand, AR-C67085MX and AR-C69931MX belong to a group of ATP derivatives that are specific antagonists of the P2Y 12 receptor and inhibit platelet aggregation at nanomolar concentrations (Ingall et al., 1999) . At the recombinant P2Y 12 receptor, AR-C69931MX had an IC 50 of 2.4 nM (Takasaki et al., 2001) . In AG32 cells expressing the P2Y 13 receptor, the IC 50 of AR-C67085MX was 0.6 M. This lower potency on the P2Y 13 receptor is consistent with the low affinity of triphosphates (ATP, 2MeSATP) mentioned earlier. However, AR-C69931MX was a very potent antagonist of the P2Y 13 receptor, with an IC 50 comparable with that obtained at the P2Y 12 receptor. Interestingly, this action of AR-C69931MX seems to be noncompetitive. MRS-2179 had no significant inhibitory effect on the P2Y 13 receptor at concentrations up to 100 M. This observation further strengthens the claim that it is a selective antagonist of the P2Y 1 receptor .
We have confirmed the observation by Zhang et al. that Ap 3 A is a potent agonist of the P2Y 13 receptor. Furthermore, we have shown that Ap 4 A, Ap 5 A, and Ap 6 A are completely inactive. The same profile has been observed with the P2Y 1 receptor (Patel et al., 2001) , suggesting that a selective sensitivity to Ap 3 A is a common feature of ADP receptors. Ap 4 A, previously shown to inhibit platelet aggregation (Zamecnik et al., 1992) , was an antagonist of the P2Y 13 receptor. Recently Ni et al. (2002) have suggested that extracellular mRNA can activate dendritic cells via an interaction between the poly[A] tail and an unidentified P2Y receptor. This conclusion was based on the observation that commercial poly [A] increased cytosolic calcium in dendritic cells, a response blocked by suramin and pertussis toxin. We have now shown that poly[A] activates the P2Y 13 receptor. Because commercial poly[A] is prepared using ADP as starting material, contamination by residual ADP may complicate the interpretation of these results. Indeed pretreatment with CP/CPK abolished the effect of poly [A] . [G] and shifted the poly [A] concentration-action curve to the right, whereas apyrase abolished its effect completely. Therefore, it is unlikely that the P2Y 13 receptor plays a role in the activation of dendritic cells by extracellular mRNA.
In conclusion, we have identified three properties that distinguish the recombinant human P2Y 13 receptor from the P2Y 12 receptor: it is less sensitive than the P2Y 12 receptor to activation by triphosphate nucleotides; the potency of 2Me-SADP is superior or equal to that of ADP, depending on the molpharm.aspetjournals.org measured endpoint; and it is antagonized less potently by AR-C67085MX and not at all by the active metabolite of clopidogrel. However, these studies have also revealed that in several respects, the P2Y 13 receptor is even more similar to the P2Y 12 than initially believed: greater potency of 2Me-SADP compared with ADP in radioligand binding assays ([ 33 P]2MeSADP, GTP␥[ 35 S]) that assess binding to the receptor or its interaction with G i , and antagonism by 2MeSAMP, Ap 4 A, and especially AR-C69931MX. These similarities between the pharmacological profiles of the hP2Y 12 and hP2Y 13 receptors seems logical when considering the high degree of amino acid identity (47.7%) and the short distance (10 kilobases) between these two syntenic genes located in tandem on 3q25 (Wittenberger et al., 2001 ).
